) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1
Search Results
Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo
Joyce LaMori, Kai Zu, Kristina L. Greenwood, Besa Smith, Tyler Smith, and Alaina Lee
’ psychosocial problems may be targets to prevent unplanned acute care utilization (“readmission”). Methods: The study included 933 unique adult patients admitted to four acute care inpatient facilities within a non-profit community based healthcare system in
Adam C. Powell, Christopher T Lugo, Jeremy T Pickerell, James W Long, Amin J Mirhadi, and Bryan A Loy
significantly less likely to deem orders appropriate for older patients (OR: 0.97; CI: 0.96-0.98), urban patients (OR: 0.75; CI: 0.61-0.90), and patients with a history of breast MRI (OR: 0.66; CI: 0.54-0.81). Orders for patients from communities with median
Robin M. Lally, Elizabeth Reed, and Roksana Zak
an expert medical oncologist known in the community. Ease of access was supported by hosting pathways on a newly developed Pathwaytocure.org website along with expert-developed, NCCN guideline supported, educational webinars. Transparency was
Ran Jin, Neil Accortt, Darcie Sandschafer, Tatiana Lawrence, and Reshma Mahtani
geographically diverse, and includes more than 2.2 million US cancer patients (primarily treated in a community setting) from >280 cancer clinics. Results: First use of trastuzumab-anns was in early stage BC (eBC) and occurred 4 days after product launch. 2
Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint
was 154 days. Majority (60%) were treated at academic and 24% at comprehensive community. Only 28% achieved complete pathological complete response rate (Tis or T0). On univariate analysis patients receiving surgery within 30 weeks of diagnosis had
happens in the community. A number of factors influence the administration of chemotherapy. For example, younger age and having private insurance are associated with higher rates. 2 The very low rates of crossover to the maintenance therapy in the
Prakash Manoharan, Ahmed Salem, Hitesh Mistry, and Corinne Faivre-Finn
controlled trial is required to settle this debate. However, in our view, there is little interest in conducting such a trial among the oncology and imaging communities. We encourage continued debate and reflection of published data regarding the impact of
Staff
thoughtful commentaries and editorials, often from Dr. Winn and the panel chairs who serve as issue editors. This themed model served JNCCN well, and the journal enjoyed early success in the oncology community as measured by independent readership surveys
Robert C. Young
guidelines would benefit both the NCCN Member Institutions and the oncology community in general. However, once the decision to proceed was made, the organization faced 2 substantial challenges: traditional support from the pharmaceutical industry was
